Post-earnings recap
Reported
Tue, Mar 28, 2023
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
25%
Est. EPS
—
Est. Rev
—
Impl. Move
—
Corvus Pharmaceuticals reported an EPS of -$0.21, but there was no revenue reported or guidance provided. The stock reacted with a slight decline of 0.29%, indicating that investors may be cautious due to the lack of detailed information and guidance from management.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.21 | N/A | — |
| Revenue | — | N/A | — |
No transcript is on record, and the analysis is based on numerical results only.